Despite these beneficial metabolic effects, native GLP-1 has significant pharmacokinetic limitations that restrict its therapeutic utility
There are two primary incretin hormones
Starting GLP-1 use with shared decision-making Like many medicines and treatments for chronic illnesses, the use of a GLP-1 is a decision that patients should make with the guidance of their providers
The continued innovation in T2D medication aims to further address the unmet needs in the diabetic population, particularly around ease of use, efficacy, and overall benefits beyond glycemic control
Over timeparticularly as patients transition from the active-weight-loss phase to long-term maintenancethe psychological burden of ongoing injections can become more apparent, Akshay Jain, a clinical instructor at the University of British Columbia, told me